We have assigned BNK a value of $1.12 per share. The valuation is based on a PE multiple of 10x the FY21 forecast EPS plus the current value of the net trailing commission receivable per share. This represents an upside of 72.3% on the share price of $0.65 at 4 September 2020.

PTX is a clinical stage oncology company with a focus on developing targeted and cellular cancer therapies. Targeted therapies are a focus for anticancer drug development, with the aim of personalising treatment based on a person’s genes and proteins to prevent, diagnose and treat the disease

Our base case valuation of Triangle Energy is A$0.14/sh per share. 50% of that value is driven by risked exploration upside. Our risk factor is 20%. The valuation ranges in the table below assume long term oil prices of A$55/bbl at the low end to A$95/bbl at the high end. Given historical oil prices, this is not an aggressive price range.

We cannot value Prospective Resources and there are no easily comparable pure play helium companies that can be used as valuation comparisons. We have constructed a Indicative Financial Model of what a project would look like based on reserves the same size as the announced Prospective Resource. At an ex-field selling price of US$200/Mscf for A Grade helium, that Indicative Project would be worth between US$18 million and US$176 million

The coronavirus pandemic has seen unprecedented measures put in place, the ramifications of which has stretched far and wide. Pharma and biotech has been not been immune to the impacts of coronavirus. One of the key disruptions has been delays to clinical trials with access to participants restricted and hospital resources prioritised for coronavirus patients